Oncorena AB, which is developing a new and potentially groundbreaking treatment for patients with advanced kidney cancer, announces that the Board of Directors of Oncorena AB has appointed Professor Börje Haraldsson as CEO of the company, effective as of today. He thus succeeds Dr. Lars Grundemar, who will leave the company. Professor Börje Haraldsson (MD, PhD, FASN, FAST) is one of the founders of Oncorena. He has played a crucial role in the development of...